Announcements Trials
Browse Landscape

Phase

Phase 1/2 6Phase 1 4Phase 2 3Phase 3 1

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 29Dermatologic 19Head & Neck 18Gastrointestinal 11Genitourinary 8Sarcoma 6Breast 5Tumor-Agnostic 4Other solid neoplasm 3Gynecologic 3Endocrine 3CNS 3Lymphoid 2Plasma cell 1

Conditions

Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Recurrence 1Ovarian Neoplasms 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1Adenocarcinoma 1

Interventions

Paclitaxel 233Carboplatin 217Bevacizumab 139Cisplatin 136pembrolizumab 89Gemcitabine 69olaparib 54Docetaxel 47Topotecan 44Radiotherapy 43liposomal doxorubicin 41Taxes 41niraparib 38Cyclophosphamide 36Doxorubicin 30Drug Therapy 29Letrozole 28Nivolumab 27Magnetic Resonance Spectroscopy 25Immunoglobulin G 25Disulfides 24Oxaliplatin 23Albumin-Bound Paclitaxel 23durvalumab 22apatinib 21Etoposide 21Brachytherapy 21lenvatinib 20camrelizumab 20Specimen Handling 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × cemiplimab × Gynecologic × Clear all
NCT06787612 2026-05-20

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Regeneron Pharmaceuticals

Phase 2 Recruiting
220 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04646005 2025-09-08

Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

Regeneron Pharmaceuticals

Phase 2 Completed
113 enrolled 18 charts
Gynecologic

Adenocarcinoma, Uterine Cervical Neoplasms, Neoplasm Metastasis, Recurrence

NCT07101848 2025-08-03

BRAVA VULVAR

Hospital Israelita Albert Einstein

Phase 2 Not yet recruiting
42 enrolled
Gynecologic

Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡